Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders

CRANBURY, N.J., May 08, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel...
May 07, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates

Galafold 1Q2020 Revenue of $60.5 Million Reflects Continued Strong Adoption in All Key Global Regions, On Track to Achieve 2020 Revenue Guidance of $250M-$260M AT-GAA in Late-Onset Pompe Disease...
May 06, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

UPDATE – Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting

CRANBURY, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel...
May 05, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting

CRANBURY, N.J., May 05, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel...
April 24, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020

CRANBURY, N.J., April 24, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 7, 2020 at...
March 23, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees

CRANBURY, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel...
March 05, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia

Significantly Expands Company’s R&D Capabilities to Advance Industry’s Largest Portfolio of Rare Disease Gene Therapy Programs State of the Art 75,000 Sq. Ft. Research Facility Across From...
March 02, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates

2019 Galafold Revenue Nearly Doubled to $182.2M On Track to Achieve 2020 Revenue Guidance of $250M-$260M Focused on Pompe Phase 3 PROPEL Study, Manufacturing to Support 2021 BLA and MAA, and...
February 26, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference

CRANBURY, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Cowen &...
February 19, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce Full-Year 2019 Financial Results on March 2, 2020

CRANBURY, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 2, 2020 at...